academic article

• Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis..  Rheumatology (Oxford, England).  56:v17-v22. 2017
• Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales..  Digestive diseases and sciences.  62:1186-1192. 2017
• Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis.  Rheumatology.  2017
• Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population.  Neurogastroenterology and Motility.  2017
• Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales.  Digestive Diseases and Sciences.  2017
• Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma- Scleroderma Clinical Trials Consortium Gastrointestinal Working Group.  Arthritis & Rheumatology.  2016
• Corrigendum: development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales..  The American journal of gastroenterology.  110:-. 2015
• Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales (vol 109, pg 1804, 2014).  The American Journal of Gastroenterology.  2015
• Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis..  Arthritis care & research.  66:1725-30. 2014
• Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales..  The American journal of gastroenterology.  109:1804-14. 2014
• GERD symptoms in the general population: prevalence and severity versus care-seeking patients..  Digestive diseases and sciences.  59:2488-96. 2014
• Construct Validity of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis.  Arthritis Care & Research.  2014
• DEVELOPMENT AND VALIDATION OF PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS (R)) GASTROINTESTINAL (GI) SYMPTOM SCALES IN SYSTEMIC SCLEROSIS.  Annals of the Rheumatic Diseases.  2014
• Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database.  The American Journal of Gastroenterology.  2014
• Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales.  The American Journal of Gastroenterology.  2014
• EVALUATION OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS (R)) GASTROINTESTINAL(GI) SYMPTOMS MEASURES IN SYSTEMIC SCLEROSIS (SSC).  Clinical and Experimental Rheumatology.  2014
• GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients.  Digestive Diseases and Sciences.  2014
• Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database..  The American journal of gastroenterology.  109:234-48. 2013
• Development Of Patient-Reported Outcomes Measurement Information System (PROMIS (R)) Gastrointestinal (GI) Symptoms Item Bank.  Arthritis & Rheumatism-arthritis Care & Research.  2013
• Differences in Gastrointestinal Symptom Severity Between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) Patients and the General Population < B/>.  Gastroenterology.  2013
• Evaluation Of The Construct Validity Of The Patient-Reported Outcomes Measurement Information System (PROMIS (R)) Gastrointestinal (GI) Symptoms Measures In Systemic Sclerosis (SSc).  Arthritis & Rheumatism-arthritis Care & Research.  2013
• Gender and Group Differences in Gastrointestinal Symptom Severity Between Irritable Bowel Syndrome and Inflammatory Bowel Disease Patients and the General Population.  Gastroenterology.  2013
• How Well Do Physicians Perceive Severity of Patients' Gastrointestinal Symptoms? A Comparison Across Disease States.  Gastroenterology.  2013
• Feasibility and Construct Validity of PROMIS and "Legacy" Instruments in an Academic Scleroderma Clinic.  Value in Health.  2012
• The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS)..  Arthritis care & research.  63 Suppl 11:S486-90. 2011
• Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic..  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.  15:128-34. 2011
• Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument..  The Journal of rheumatology.  38:1920-4. 2011
• Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study..  Rheumatology (Oxford, England).  50:1280-7. 2011
• Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study..  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.  20:1131-40. 2011
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.  Rheumatology.  2011
• Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study.  Quality of Life Research.  2011
• Impact of Acute Gout Flares on Health Related Quality of Life (HRQOL) and Productivity in Patients with Chronic Gout.  Arthritis & Rheumatism-arthritis Care & Research.  2011
• Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  The Journal of Rheumatology.  2011
• Prevalence and correlates of sleep disturbance in systemic sclerosis-results from the UCLA scleroderma quality of life study.  Rheumatology.  2011
• The Future of Measuring Patient-Reported Outcomes in Rheumatology.  Arthritis Care & Research.  2011
• Valuation of scleroderma and psoriatic arthritis health states by the general public..  Health and Quality of Life Outcomes.  -. 2010
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis..  Rheumatology (Oxford, England).  50:330-4. 2010
• Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument..  Arthritis and rheumatism.  61:1257-63. 2009
• Reliability and Validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  Arthritis & Rheumatism-arthritis Care & Research.  2009
• A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]..  Medical Decision Making.  29:7-14. 2008
• The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice..  The Journal of rheumatology.  35:2339-43. 2008
• The Minimally Important Difference for the Fatigue Visual Analog Scale in Patients with Rheumatoid Arthritis Followed in an Academic Clinical Practice.  The Journal of Rheumatology.  2008
• Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument..  Arthritis and rheumatism.  57:1280-6. 2007
• Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis..  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.  16:1083-92. 2007
• Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.  Arthritis & Rheumatism-arthritis Care & Research.  2007
• Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.  Quality of Life Research.  2007
• Assessment of SF-6D, a preference measure, in systemic sclerosis.  Arthritis & Rheumatism-arthritis Care & Research.  2006
• Development of the scleroderma gastrointestinal tract 1.0 (SSc-GIT1.0) quality of life instrument - Preliminary report.  Arthritis & Rheumatism-arthritis Care & Research.  2006
• Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.  Annals of the Rheumatic Diseases.  2006
• Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial..  The Journal of rheumatology.  32:832-40. 2005
• Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.  The Journal of Rheumatology.  2005
• Responsiveness of the health related quality of life (HRQL)instruments (SF-36 and HAQ-DI) in a systemic sclerosis (SSc) clinical trial.  Arthritis & Rheumatism-arthritis Care & Research.  2003